Chronic Myelomonocytic Leukemia (CMML)
Oncology·MeSH: Leukemia, Myeloid, Acute
Prevalence
0.5 / 100K
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Preclinical(1)
| Drug | Company |
|---|---|
| lenzilumab | HUMANIGEN, INC (HGEN) |
Frequently asked questions
How many drugs are in development for Chronic Myelomonocytic Leukemia (CMML)?
BioSniper tracks 1 drug in development for Chronic Myelomonocytic Leukemia (CMML) across 1 company.
How many clinical trials target Chronic Myelomonocytic Leukemia (CMML)?
There are 4 clinical trials targeting Chronic Myelomonocytic Leukemia (CMML) tracked by BioSniper.
What is the prevalence of Chronic Myelomonocytic Leukemia (CMML)?
The estimated prevalence of Chronic Myelomonocytic Leukemia (CMML) is approximately 0.5 per 100,000 population.
Deep-dive into Chronic Myelomonocytic Leukemia (CMML)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis